SIV infection and immunotherapies at ART initiation in infant macaques.

(A), Experimental design. Twenty-one infant rhesus macaques were orally challenged with SIV_mac251 at 4 weeks of life. ART was started 1–2 weeks post infection. RMs were then divided into three groups: ART only controls (n = 7); ART + SIV RhmAbs (n = 7) and ART + SIV RhmAbs + N-803 (n = 7; *2 animals were prematurely euthanized due to adverse events resulting in a final n = 5). Animals received a single dose of SIV RhmAbs at 20 mg/kg s.c. each and a single dose of N-803 at 0.1 mg/kg. Both SIV RhmAbs and N-803 were administered on the same day as ART was initiated. ATI, Analytical Treatment Interruption. Created with Biorender.com. (B), Plasma concentrations of each SIV RhmAbs in μg/ml in the ART + SIV RhmAbs and ART + SIV RhmAbs + N-803 days post treatment. (C), Half-life of SIV RhmAbs in ART + SIV RhmAbs and ART + SIV RhmAbs + N-803 treated group. Individual data points are plotted with horizontal line drawn at the median.